Premium
Small Pharma Inc (DMT)
TSXV
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17...
• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma, supporting the combined company’s vision to build an international clinical-stage leader in psychedelic-based...
Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE...
• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma LONDON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or...
LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “Company”) between September 25, 2023 and...
• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the...
- Durch den Erwerb sämtlicher Aktien wird ein international führendes Unternehmen für neuartige psychedelische Therapeutika in der klinischen Phase geschaffen - - Es befinden sich zwei...
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety...
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
